People v. Barker

2022 IL App (4th) 210088-U
Appellate Court of Illinois·Decided November 16, 2022·No. 4-21-0088·Unpublished·Cited by 1 cases

Opinion

NOTICE 2022 IL App (4th) 210088-U FILED This Order was filed under November 16, 2022 Supreme Court Rule 23 and is NO. 4-21-0088 Carla Bender

not precedent except in the limited circumstances allowed IN THE APPELLATE COURT 4th District Appellate under Rule 23(e)(1). Court, IL OF ILLINOIS

FOURTH DISTRICT

THE PEOPLE OF THE STATE OF ILLINOIS, ) Appeal from the Plaintiff-Appellee, ) Circuit Court of v. ) Champaign County PARIS J. BARKER, ) No. 17CF494 Defendant-Appellant. )

) Honorable

) Randall B. Rosenbaum, ) Judge Presiding.

JUSTICE CAVANAGH delivered the judgment of the court.

Justices Turner and Harris concurred in the judgment.

ORDER

¶1 Held: The appellate court affirmed, concluding the trial court did not abuse its discretion when it resentenced defendant following the revocation of her probation to the minimum term of three years in prison for the Class 2 felony offense of identity theft.

¶2 Defendant, Paris J. Barker, appeals from the trial court’s judgment sentencing her to three years in prison for the Class 2 felony offense of identity theft (720 ILCS 5/16-30(a)(1), (e)(1)(A)(iii) (West 2016)). She argues the court abused its discretion when it resentenced her based on her conduct while on drug court probation rather than on the underlying offense. The State argues the court did not abuse its discretion and its sentence was proper. We affirm.

¶3 I. BACKGROUND

¶4 On April 18, 2017, the State charged defendant with three counts of identity theft—

of which two were Class 2 felonies and one was a Class 3 felony, depending on the value of the

property stolen. See id. §§ 16-30(a)(1), (e)(1)(A)(iii), (e)(1)(A)(ii). The State alleged defendant knowingly used another person’s name, information, and credit card to obtain credit from various third parties.

¶5 On January 11, 2018, defendant advised the trial court she wished to participate in drug court probation. The court thoroughly explained the conditions of drug court and the expectations of defendant. She agreed, indicated she had consulted with her attorney, and had no questions regarding the program. Defendant pleaded guilty to one count—a Class 2 felony. The court advised defendant the possible sentence for a Class 2 felony was “not less than three nor more than seven years in the penitentiary.” Defendant stated she understood.

¶6 The State provided the following factual basis for defendant’s plea. On May 16, 2015, defendant used Perry Beal’s credit card without his permission to pay her bond in a pending Champaign County traffic case. Defendant also made recorded jail calls to an unknown party giving Beal’s name and credit card number. On May 19, 2015, Beal was informed by One Main Financial that a $10,000 loan was opened by defendant in his name. Defendant also used Beal’s information to pay a lease, a Verizon Wireless bill, and an Ameren Illinois bill, totaling $3331.07.

¶7 The court accepted defendant’s guilty plea and, pursuant to the plea agreement, placed defendant on 48 months’ drug court probation.

¶8 On June 5, 2019, the trial court entered an order of imprisonment for 180 days after defendant was found to have benzodiazepines in her system because of medication administered while she was in the county jail. She admitted to telling jail personnel, when asked, that she was “still taking medication.” Based on defendant’s intentional misrepresentation to jail personnel, the court ordered her into custody and to write an essay. Defendant submitted a letter to the court

admitting she had lied to jail personnel. Given defendant’s confession of deceit, the court allowed her to be released from jail.

¶9 However, on August 17, 2020, the State filed a petition to revoke defendant’s probation because she had violated multiple conditions. The State alleged defendant’s urinalysis testing submitted on August 4, 2020, returned positive for tramadol and fentanyl. The State further alleged defendant failed to submit specimens “as directed” on May 13, 2020, May 20, 2020, and August 4, 2020. The State later advised the court it was proceeding only on defendant’s failure to submit on May 13, 2020.

¶ 10 On September 9, 2020, the trial court conducted a hearing on the State’s petition. Mark Dotson, the case manager for the drug court team at Rosecrance, testified defendant “did not show for a drop nor did she call to inform us that she had any obstruction to making it on time for the drop” on May 13, 2020.

¶ 11 Caren Cohen-Heath, an addiction counselor at Rosecrance, testified she performed the urinalysis of defendant on August 4, 2020. Defendant tested positive for tramadol, fentanyl, and opiates.

¶ 12 Zac Dawkins, the problem-solving court coordinator for Champaign County, testified he determined who submitted to drug drops on any day. Dawkins testified defendant was required to submit on May 13, 2020. His duties also included retrieving positive samples from Rosecrance and delivering them to the probation department. He said he retrieved a positive sample from defendant’s August 4, 2020, drop.

¶ 13 Heather Rumple, an officer with the Champaign County Probation and Court Services Department, testified she performed confirmation of positive or borderline drug tests from

Rosecrance. On August 6, 2020, she tested defendant’s sample submitted on August 4, 2020, and confirmed, with two tests, the sample was positive for tramadol and fentanyl.

¶ 14 The trial court continued the hearing to allow defendant the opportunity to present a witness from a private testing agency. On November 9, 2020, the hearing resumed. At the State’s request, the court took judicial notice of “the court file in this case, the drug court order, and the conditions of [defendant’s] drug court probation, as well as the fact that tramadol and fentanyl are controlled substances.”

¶ 15 Defendant presented the testimony of Liaqat Ali Abbas, a stipulated expert with the United States Drug Testing Laboratories, Inc. Dr. Abbas testified he was in possession of defendant’s hair sample, taken on September 16, 2020, which was tested for “amphetamines, barbiturates, benzodiazepines, cocaines, methadones, meperidine, opiates, phenylcyclohexyl piperidine, oxycodone, proposyphene, cannabinoids, tramadol, fentanyl, and sufentanil.” The sample was negative for all drugs except cannabinoids. The test was “presumptive positive” but there was not enough of a sample to test for a confirmatory test. He said these drugs stay in the hair for “up to about 90 days for this test” but would degrade more quickly with hair coloring or the like. Abbas also testified the hair test was not ideal to prove a single use. That is, he said, a urine test would be more accurate to determine whether a person consumed a particular drug on a particular day. Abbas testified: “Again, a hair test would not pick up a single use” for any drug.

¶ 16 Defendant testified she had been clean from opiates since September 11, 2017. When she was advised she had tested positive on August 4, 2020, she was glad to hear Rosecrance would be sending the sample to Rumple because “they ha[d] the machine there to test it.” She denied using any drugs except the one she was given in jail in May 2019 to help her sleep. She

said: “I would never jeopardize anything I have going on for fentanyl or tramadol.” She also denied getting any treatments done on her hair.

¶ 17 After considering the evidence and arguments of counsel, the trial court found the State had proved by a preponderance of the evidence defendant had violated the terms of her probation by not submitting to testing on May 13, 2020, and testing positive for controlled substances on August 4, 2020.

Free access — add to your briefcase to read the full text and ask questions with AI

People v. Barker, 2022 IL App (4th) 210088-U (Ill. Ct. App. 2022).

2022 IL App (4th) 210088-U (People v. Barker) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

People v. Rodriguez
2025 IL App (4th) 250108-U (Appellate Court of Illinois, 2025)